Skip to main content
SpringerLink
Log in

Chemoprevention for Esophageal Carcinoma

  • Chapter
Esophageal Cancer

  • 1606 Accesses

Abstract

Prevention is the most desirable strategy for nearly all disease processes, but this is especially true for a malignancy with a tendency for metastasis and a correspondingly poor prognosis. Chemoprevention through appropriate drug treatment is a potentially powerful means of radically reducing the incidence of esophageal cancer, and the search for clinically effective agents has now led to large multicenter randomized controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bazuro GE, Torino F, Gasparini G, et al. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol. 2008;54:429–44. http://www.ncbi.nlm.nih.gov/pubmed/19047983. Accessed 15 Aug 2014.

    CAS  PubMed  Google Scholar 

  2. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120–8. doi:10.1172/JCI119018.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Clemons NJ, McColl KEL, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett’s esophagus carcinogenesis via distinct mechanisms. Gastroenterology. 2007;133:1198–209. doi:10.1053/j.gastro.2007.06.061.

    Article  CAS  PubMed  Google Scholar 

  4. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327–35. http://www.ncbi.nlm.nih.gov/pubmed/10419913. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  5. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487–96. http://www.ncbi.nlm.nih.gov/pubmed/10702199. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  6. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett’s carcinogenesis. Clin Cancer Res. 2004;10:4784–92. doi:10.1158/1078-0432.CCR-04-0015.

    Article  CAS  PubMed  Google Scholar 

  7. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 1995;9:451–4. http://www.ncbi.nlm.nih.gov/pubmed/8527623. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  8. Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther. 1998;12:893–7. http://www.ncbi.nlm.nih.gov/pubmed/9768533. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  9. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett’s) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther. 1993;7:623–8. http://www.ncbi.nlm.nih.gov/pubmed/8161668. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  10. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 1996;44:700–5. http://www.ncbi.nlm.nih.gov/pubmed/8979061. Accessed 26 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  11. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45:489–94. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1727665&tool=pmcentrez&rendertype=abstract. Accessed 26 Aug 2014.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Triadafilopoulos G. Proton pump inhibitors for Barrett’s oesophagus. Gut. 2000;46:144–6. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1727807&tool=pmcentrez&rendertype=abstract. Accessed 15 Aug 2014.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877–83. doi:10.1111/j.1572-0241.2004.30228.x.

    Article  CAS  PubMed  Google Scholar 

  14. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7:1299–304. doi:10.1016/j.cgh.2009.06.001.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42. doi:10.1136/gutjnl-2013-305372.

    Article  PubMed  Google Scholar 

  16. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41. doi:10.1016/S0140-6736(10)62110-1.

    Article  CAS  PubMed  Google Scholar 

  17. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56. doi:10.1053/gast.2003.50008.

    Article  CAS  PubMed  Google Scholar 

  18. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–52.e5. doi:10.1053/j.gastro.2011.11.019; quiz e22–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Sadeghi S, Bain CJ, Pandeya N, et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008;17:1169–78. doi:10.1158/1055-9965.EPI-07-2852.

    Article  CAS  PubMed  Google Scholar 

  20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–9. http://www.ncbi.nlm.nih.gov/pubmed/11509060. Accessed 12 Jan 2015.

    Article  CAS  PubMed  Google Scholar 

  21. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071–3. doi:10.1016/S0140-6736(02)11131-7.

    Article  CAS  PubMed  Google Scholar 

  22. Rees JR, Lao-Sirieix P, Wong A, et al. Treatment for Barrett’s oesophagus. Cochrane database Syst Rev. 2010:CD004060. doi:10.1002/14651858.CD004060.pub2.

  23. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–7. doi:10.1016/S1470-2045(09)70035-X.

    Article  CAS  PubMed  Google Scholar 

  24. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–9. http://www.ncbi.nlm.nih.gov/pubmed/19213566. Accessed 15 Aug 2014.

    Article  CAS  PubMed  Google Scholar 

  25. Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiol Biomarkers Prev. 2008;17:1858–61. doi:10.1158/1055-9965.EPI-07-0710.

    Article  CAS  PubMed  Google Scholar 

  26. Beales ILP, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 2013;4:69–79. doi:10.4292/wjgpt.v4.i3.69.

    PubMed Central  PubMed  Google Scholar 

  27. Ullah MF, Bhat SH, Husain E, et al. Pharmacological intervention through dietary nutraceuticals in gastrointestinal neoplasia. Crit Rev Food Sci Nutr. 2014. doi:10.1080/10408398.2013.772091.

  28. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007;81:519–33. doi:10.1016/j.lfs.2007.06.011.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82:1807–21. doi:10.1016/j.bcp.2011.07.093.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Nechuta S, Shu X-O, Li H-L, et al. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women’s Health Study. Am J Clin Nutr. 2012;96:1056–63. doi:10.3945/ajcn.111.031419.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Gao YT, McLaughlin JK, Blot WJ, et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst. 1994;86:855–8. http://www.ncbi.nlm.nih.gov/pubmed/8182766. Accessed 12 Jan 2015.

    Article  CAS  PubMed  Google Scholar 

  32. Wang ZY, Wang LD, Lee MJ, et al. Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis. 1995;16:2143–8. http://www.ncbi.nlm.nih.gov/pubmed/7554067. Accessed 12 Jan 2015.

    Article  CAS  PubMed  Google Scholar 

  33. Li ZG, Shimada Y, Sato F, et al. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats. Int J Oncol. 2002;21:1275–83. http://www.ncbi.nlm.nih.gov/pubmed/12429978. Accessed 12 Jan 2015.

    CAS  PubMed  Google Scholar 

  34. Maliakal P, Sankpal UT, Basha R, et al. Relevance of drug metabolizing enzyme activity modulation by tea polyphenols in the inhibition of esophageal tumorigenesis. Med Chem (Los Angeles). 2011;7:480–7. http://www.ncbi.nlm.nih.gov/pubmed/21801144. Accessed 7 Jan 2015.

    CAS  Google Scholar 

  35. Song S, Krishnan K, Liu K, et al. Polyphenon E inhibits the growth of human Barrett’s and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin Cancer Res. 2009;15:622–31. doi:10.1158/1078-0432.CCR-08-0772.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Bobe G, Peterson JJ, Gridley G, et al. Flavonoid consumption and esophageal cancer among black and white men in the United States. Int J Cancer. 2009;125:1147–54. doi:10.1002/ijc.24421.

    Article  CAS  PubMed  Google Scholar 

  37. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5. http://www.ncbi.nlm.nih.gov/pubmed/3106339. Accessed 12 Jan 2015.

    CAS  PubMed  Google Scholar 

  38. Dong J-Y, Qin L-Q. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315–23. doi:10.1007/s10549-010-1270-8.

    Article  CAS  PubMed  Google Scholar 

  39. Rossi M, Bosetti C, Negri E, et al. Flavonoids, proanthocyanidins, and cancer risk: a network of case-control studies from Italy. Nutr Cancer. 2010;62:871–7. doi:10.1080/01635581.2010.509534.

    Article  CAS  PubMed  Google Scholar 

  40. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38. doi:10.1080/21551197.2012.702534.

    Article  PubMed  Google Scholar 

  41. Rossi M, Garavello W, Talamini R, et al. Flavonoids and risk of squamous cell esophageal cancer. Int J Cancer. 2007;120:1560–4. doi:10.1002/ijc.22499.

    Article  CAS  PubMed  Google Scholar 

  42. Dawsey SP, Hollenbeck A, Schatzkin A, et al. A prospective study of vitamin and mineral supplement use and the risk of upper gastrointestinal cancers. PLoS One. 2014;9:e88774. doi:10.1371/journal.pone.0088774.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Bjelakovic G, Nikolova D, Simonetti RG, et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364:1219–28. doi:10.1016/S0140-6736(04)17138-9.

    Article  CAS  PubMed  Google Scholar 

  44. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–900. http://www.ncbi.nlm.nih.gov/pubmed/11712783. Accessed 12 Jan 2015.

    CAS  PubMed  Google Scholar 

  45. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4:354–64. doi:10.1158/1940-6207.CAPR-10-0098.

    Article  CAS  Google Scholar 

  46. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4:1035–8. doi:10.1016/j.cgh.2006.03.020.

    Article  CAS  PubMed  Google Scholar 

  47. Garcea G, Berry DP, Jones DJL, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005;14:120–5. http://www.ncbi.nlm.nih.gov/pubmed/15668484. Accessed 12 Jan 2015.

    CAS  PubMed  Google Scholar 

  48. Ushida J, Sugie S, Kawabata K, et al. Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J cancer Res. 2000;91:893–8. http://www.ncbi.nlm.nih.gov/pubmed/11011116. Accessed 12 Jan 2015.

    Article  CAS  PubMed  Google Scholar 

  49. Subramaniam D, Ponnurangam S, Ramamoorthy P, et al. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One. 2012;7:e30590. doi:10.1371/journal.pone.0030590.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biophotonics Research Unit, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Great Western Road, Gloucester, GL1 3NN, UK

    Oliver J. Old

  2. Upper GI Surgery Department, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Newcastle Road, Stoke-on-Trent, ST4 6Q, UK

    L. Max Almond

  3. Upper GI Surgery Department, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Great Western Road, Gloucester, GL1 3NN, UK

    Hugh Barr MD, ChM, FRCS, FRCSE, FHEA

  4. University Hospitals Coventry & Warwickshire NHS Trust, Warwick Medical School, University of Warwick, Warwickshire, CV2 2DX, UK

    Janusz Jankowski

Authors
  1. Oliver J. Old
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Max Almond
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugh Barr MD, ChM, FRCS, FRCSE, FHEA
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janusz Jankowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janusz Jankowski .

Editor information

Editors and Affiliations

  1. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

    Nabil F. Saba

  2. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

    Bassel F. El-Rayes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Old, O.J., Almond, L.M., Barr, H., Jankowski, J. (2015). Chemoprevention for Esophageal Carcinoma. In: Saba, N., El-Rayes, B. (eds) Esophageal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-20068-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20068-2_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20067-5

  • Online ISBN: 978-3-319-20068-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation